FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W3116349168> ?p ?o ?g. }

• W3116349168 endingPage "e445" @default.
• W3116349168 startingPage "e437" @default.
• W3116349168 abstract "Abstract Objective The aim of the study is to describe the real-world use of the P2Y12 inhibitor cangrelor as a bridging strategy in patients at high thrombotic risk after percutaneous coronary intervention (PCI) and referred to surgery requiring perioperative withdrawal of dual antiplatelet therapy (DAPT). Materials and Methods We collected data from nine Italian centers on patients with previous PCI who were still on DAPT and undergoing nondeferrable surgery requiring DAPT discontinuation. A perioperative standardized bridging protocol with cangrelor was used. Results Between December 2017 and April 2019, 24 patients (mean age 72 years; male 79%) were enrolled. All patients were at high thrombotic risk after PCI and required nondeferrable intermediate to high bleeding risk surgery requiring DAPT discontinuation (4.6 ± 1.7 days). Cangrelor infusion was started at a bridging dose (0.75 µg/kg/min) 3 days before planned surgery and was discontinued 6.6 ± 1.5 hours prior to surgical incision. In 55% of patients, cangrelor was resumed at 9 ± 6 hours following surgery for a mean of 39 ± 38 hours. One cardiac death was reported after 3 hours of cangrelor discontinuation prior to surgery. No ischemic outcomes occurred after surgery and up to 30-days follow-up. The mean hemoglobin drop was <2 g/dL; nine patients received blood transfusions consistent with the type of surgery, but no life-threatening or fatal bleeding occurred. Conclusion Perioperative bridging therapy with cangrelor is a feasible approach for stented patients at high thrombotic risk and referred to surgery requiring DAPT discontinuation. Larger studies are warranted to support the safety of this strategy." @default.
• W3116349168 created "2021-01-05" @default.
• W3116349168 creator A5004617206 @default.
• W3116349168 creator A5007432771 @default.
• W3116349168 creator A5009905059 @default.
• W3116349168 creator A5014610079 @default.
• W3116349168 creator A5015330640 @default.
• W3116349168 creator A5015992129 @default.
• W3116349168 creator A5021600420 @default.
• W3116349168 creator A5025023227 @default.
• W3116349168 creator A5029034896 @default.
• W3116349168 creator A5033474315 @default.
• W3116349168 creator A5036345322 @default.
• W3116349168 creator A5040418600 @default.
• W3116349168 creator A5041705296 @default.
• W3116349168 creator A5045722175 @default.
• W3116349168 creator A5050815815 @default.
• W3116349168 creator A5059983020 @default.
• W3116349168 creator A5062552702 @default.
• W3116349168 creator A5070194539 @default.
• W3116349168 creator A5070851608 @default.
• W3116349168 creator A5087752577 @default.
• W3116349168 date "2020-10-01" @default.
• W3116349168 modified "2023-10-13" @default.
• W3116349168 title "Antiplatelet Therapy with Cangrelor in Patients Undergoing Surgery after Coronary Stent Implantation: A Real-World Bridging Protocol Experience" @default.
• W3116349168 cites W1594634064 @default.
• W3116349168 cites W1978591428 @default.
• W3116349168 cites W1997674826 @default.
• W3116349168 cites W1998407948 @default.
• W3116349168 cites W2031100314 @default.
• W3116349168 cites W2039578887 @default.
• W3116349168 cites W2065390746 @default.
• W3116349168 cites W2065824855 @default.
• W3116349168 cites W2082786825 @default.
• W3116349168 cites W2087150869 @default.
• W3116349168 cites W2111548709 @default.
• W3116349168 cites W2116794265 @default.
• W3116349168 cites W2128797241 @default.
• W3116349168 cites W2150651700 @default.
• W3116349168 cites W2150655309 @default.
• W3116349168 cites W2159980301 @default.
• W3116349168 cites W2165031866 @default.
• W3116349168 cites W2184720681 @default.
• W3116349168 cites W2285459543 @default.
• W3116349168 cites W2305891734 @default.
• W3116349168 cites W2331820709 @default.
• W3116349168 cites W2495971683 @default.
• W3116349168 cites W2500434105 @default.
• W3116349168 cites W2564420797 @default.
• W3116349168 cites W2565424709 @default.
• W3116349168 cites W2752033985 @default.
• W3116349168 cites W2766257307 @default.
• W3116349168 cites W2789272589 @default.
• W3116349168 cites W2792633859 @default.
• W3116349168 cites W2796733946 @default.
• W3116349168 cites W2809879775 @default.
• W3116349168 cites W2809976815 @default.
• W3116349168 cites W2888219742 @default.
• W3116349168 cites W2888227991 @default.
• W3116349168 cites W2900684021 @default.
• W3116349168 cites W2902635828 @default.
• W3116349168 cites W2909175318 @default.
• W3116349168 cites W2910833684 @default.
• W3116349168 cites W2916912835 @default.
• W3116349168 cites W2968201211 @default.
• W3116349168 cites W4239553742 @default.
• W3116349168 doi "https://doi.org/10.1055/s-0040-1721504" @default.
• W3116349168 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/7758156" @default.
• W3116349168 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/33376943" @default.
• W3116349168 hasPublicationYear "2020" @default.
• W3116349168 type Work @default.
• W3116349168 sameAs 3116349168 @default.
• W3116349168 citedByCount "11" @default.
• W3116349168 countsByYear W31163491682021 @default.
• W3116349168 countsByYear W31163491682022 @default.
• W3116349168 countsByYear W31163491682023 @default.
• W3116349168 crossrefType "journal-article" @default.
• W3116349168 hasAuthorship W3116349168A5004617206 @default.
• W3116349168 hasAuthorship W3116349168A5007432771 @default.
• W3116349168 hasAuthorship W3116349168A5009905059 @default.
• W3116349168 hasAuthorship W3116349168A5014610079 @default.
• W3116349168 hasAuthorship W3116349168A5015330640 @default.
• W3116349168 hasAuthorship W3116349168A5015992129 @default.
• W3116349168 hasAuthorship W3116349168A5021600420 @default.
• W3116349168 hasAuthorship W3116349168A5025023227 @default.
• W3116349168 hasAuthorship W3116349168A5029034896 @default.
• W3116349168 hasAuthorship W3116349168A5033474315 @default.
• W3116349168 hasAuthorship W3116349168A5036345322 @default.
• W3116349168 hasAuthorship W3116349168A5040418600 @default.
• W3116349168 hasAuthorship W3116349168A5041705296 @default.
• W3116349168 hasAuthorship W3116349168A5045722175 @default.
• W3116349168 hasAuthorship W3116349168A5050815815 @default.
• W3116349168 hasAuthorship W3116349168A5059983020 @default.
• W3116349168 hasAuthorship W3116349168A5062552702 @default.
• W3116349168 hasAuthorship W3116349168A5070194539 @default.
• W3116349168 hasAuthorship W3116349168A5070851608 @default.
• W3116349168 hasAuthorship W3116349168A5087752577 @default.
• W3116349168 hasBestOaLocation W31163491681 @default.

• next